Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

NewsGuard 100/100 Score
Feb 11 2010

Amicus Therapeutics (Nasdaq: FOLD) announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.  The Company also presented encouraging data from preclinical studies evaluating the combination of pharmacological chaperones and enzyme replacement therapy (ERT) for Fabry disease and Pompe disease as well as from preclinical studies examining the use of pharmacological chaperones for the treatment of Parkinson's disease.  

SOURCE Amicus Therapeutics

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Study reveals inflammation's role in long COVID's lingering effects
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip
Vaccines targeting chronic diseases show promise in combatting age-related conditions
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions
Study finds patients with long COVID exhibit complement dysregulation with signs of thromboinflammation
Promising candidate medication for preventing and reversing fentanyl-induced overdose
Natural killer cells lead the charge in cancer treatment innovation
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New peptide library paves the way for targeting elusive cancer factor MYC